Biocon Limited reported a strong financial performance for the quarter and financial year ended March 31, 2025. For Q4FY25, consolidated revenue came in at Rs 4,454 crore, marking a 12% year-on-year (YoY) increase. On a like-for-like basis, the revenue grew 15% YoY after adjusting for revenues from Branded Formulations India (BFI).
EBITDA rose 16% YoY to Rs 1,115 crore with an EBITDA margin of 25%. Core EBITDA, excluding R&D and other adjustments, came in at Rs 1,363 crore with a margin of 31%.
The company posted a net profit of Rs 344 crore in Q4FY25, a significant 153% YoY jump. On a like-for-like basis, the net profit rose 162% YoY. Profit before tax (PBT) surged 53% YoY to Rs 487 crore.
Segmental performance
- Generics: Revenue rose 46% YoY to Rs 1,048 crore, driven by strong contributions from Lenalidomide and Dasatinib launches in the U.S.
- Biosimilars: Revenue increased 4% YoY to Rs 2,463 crore. On an adjusted basis, it rose 9% YoY.
- Research Services (Syngene): Revenue climbed 11% YoY to Rs 1,018 crore.
Full-year FY25 highlights
For the full year, Biocon reported:
- Total revenue: Rs 16,470 crore, up 5% YoY (8% like-for-like)
- EBITDA: Rs 4,374 crore, up 5% YoY
- Net profit: Rs 1,013 crore, down 1% YoY; however, like-for-like net profit increased 30%
Dividend and capital plans
The Board recommended a final dividend of Rs 0.50 per share. Additionally, it approved raising up to Rs 4,500 crore through various financial instruments for debt repayment and strategic investments.
Strategic developments
Biocon Biologics launched its fifth biosimilar, Yesintek (bUstekinumab), in the U.S. and Germany, and secured a U.S. market entry for Yesafili (bAflibercept). The company also partnered with Civica Inc. to increase access to insulins.
Syngene crossed Rs 1,000 crore in quarterly revenue for the first time and acquired a biologics manufacturing facility in the U.S., expanding its CDMO capabilities.
Biocon has also initiated an evaluation of a potential merger between Biocon Limited and Biocon Biologics.
Sustainability
Biocon and Biocon Biologics were both included in the S&P Global Sustainability Yearbook 2025, with Biocon ranked among the top 5% in the Biotechnology sector.
